Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

ESSA Pharma stock

EPIX
CA29668H7085
A2JKQ4

Price

1.79
Today +/-
-0.01
Today %
-0.56 %
P

ESSA Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the ESSA Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the ESSA Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the ESSA Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze ESSA Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

ESSA Pharma Stock Price History

DateESSA Pharma Price
11/11/20241.79 undefined
11/8/20241.80 undefined
11/7/20241.77 undefined
11/6/20241.71 undefined
11/5/20241.70 undefined
11/4/20241.63 undefined
11/1/20241.40 undefined
10/31/20245.20 undefined
10/30/20245.28 undefined
10/29/20245.41 undefined
10/28/20245.49 undefined
10/25/20245.55 undefined
10/24/20245.97 undefined
10/23/20245.37 undefined
10/22/20245.74 undefined
10/21/20246.02 undefined
10/18/20246.08 undefined
10/17/20245.77 undefined
10/16/20246.12 undefined
10/15/20245.95 undefined
10/14/20246.02 undefined

ESSA Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ESSA Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ESSA Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ESSA Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ESSA Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ESSA Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ESSA Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ESSA Pharma’s growth potential.

ESSA Pharma Revenue, EBIT and net profit per share

DateESSA Pharma RevenueESSA Pharma EBITESSA Pharma Net Income
2030e578.43 M undefined0 undefined220.49 M undefined
2029e388.39 M undefined16.21 M undefined151.69 M undefined
2028e109.88 M undefined-106.46 M undefined-40.48 M undefined
2027e44.47 M undefined-127.77 M undefined-70.75 M undefined
2026e5.68 M undefined-73.78 M undefined-17.57 M undefined
2025e0 undefined-51.08 M undefined-22.82 M undefined
2024e0 undefined-37.43 M undefined-30.7 M undefined
20230 undefined-32.14 M undefined-26.58 M undefined
20220 undefined-36.97 M undefined-35.1 M undefined
20210 undefined-37.16 M undefined-36.81 M undefined
20200 undefined-23.93 M undefined-23.45 M undefined
20190 undefined-12.15 M undefined-12.76 M undefined
20180 undefined-11.03 M undefined-11.63 M undefined
20170 undefined-16.06 M undefined-4.5 M undefined
20160 undefined-18.7 M undefined-13.14 M undefined
20150 undefined-15.84 M undefined-9.36 M undefined
20140 undefined-2.94 M undefined-1.81 M undefined
20130 undefined-1.02 M undefined-1.03 M undefined
20120 undefined-1.92 M undefined-1.93 M undefined
20110 undefined-980,000 undefined-980,000 undefined

ESSA Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
000000000000000544109388578
----------------780.00147.73255.9648.97
--------------------
00000000000000000000
0-1-1-2-15-18-16-11-12-23-37-36-32-37-51-73-127-106160
----------------1,460.00-288.64-97.254.12-
0-1-1-1-9-13-4-11-12-23-36-35-26-30-22-17-70-40151220
----800.0044.44-69.23175.009.0991.6756.52-2.78-25.7115.38-26.67-22.73311.76-42.86-477.5045.70
0.640.730.780.780.921.351.454.578.4322.4438.4844.0444.090000000
--------------------
Details

Keystats

ⓘ

Revenue and Growth

The ESSA Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the ESSA Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (k)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
0.20.80.23.71.69414.853.378.3194.9167.2148.08
0.10.200.13.8000.30.40.30.500.14
0000000000000
0000000000000
0000.11.711.10.50.61.72.21.80.59
0.310.23.97.1105.115.654.380.3197.6169148.8
000020010010000030020068.01
0000000000000
0000000000000
50050040040030030020020000000
0000000000000
000000200200300300300300257.25
500500400400500400500400300300600500325.26
0.81.50.64.37.610.45.61654.680.6198.2169.5149.12
                         
1.84.34.16.619.4262640.278.5131.1277.4278.1278.16
000000003031.236.44449.05
-1.1-3-3.6-4.6-13.2-24.4-28.2-29-57.5-81-117.8-152.9-179.46
0000-1.7-2.1-2.1-2.1-2.1-2.1-2.1-2.1-2.12
0000000000000
0.71.30.524.5-0.5-4.39.148.979.2193.9167.1145.63
00.10.20.62.13.51.60.51.40.71.412.03
000000000.20.52.51.41.47
0000010010003000000
0000000000000
00000022.83.70000
00.10.20.62.13.63.73.35.61.23.92.43.5
0000005.93.500000
0000000000000
0001.617.30.2000.10.20.10
0001.617.36.13.500.10.20.10
00.10.22.23.110.99.86.85.61.34.12.53.5
0.71.40.74.27.610.45.515.954.580.5198169.6149.12
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of ESSA Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand ESSA Pharma's financial health and stability.

Assets

ESSA Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that ESSA Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of ESSA Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into ESSA Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
0-1-1-1-9-13-4-11-12-23-36-35-26
0000000000000
0000000000000
000002-10-1-1102
0000-2-3-10321518159
0000000000000
0000000000000
-1-10-2-13-15-17-10-12-16-25-28-19
0000000000000
000000000-21-35-52-3
000000000-21-35-52-3
0000000000000
000000824-2-3000
0202122000364915100
020512221221504114100
0002024-217-3-900
0000000000000
-1003-17-51038381-80-23
-1.01-1.82-0.58-2.09-13.62-15.31-17.35-10.22-12.25-16.98-25.42-28.7-19.78
0000000000000

ESSA Pharma stock margins

The ESSA Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ESSA Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ESSA Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ESSA Pharma's sales revenue. A higher gross margin percentage indicates that the ESSA Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ESSA Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ESSA Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ESSA Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ESSA Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ESSA Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ESSA Pharma Margin History

ESSA Pharma Gross marginESSA Pharma Profit marginESSA Pharma EBIT marginESSA Pharma Profit margin
2030e0 %0 %38.12 %
2029e0 %4.17 %39.06 %
2028e0 %-96.88 %-36.84 %
2027e0 %-287.3 %-159.08 %
2026e0 %-1,298.98 %-309.29 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %

ESSA Pharma Stock Sales Revenue, EBIT, Earnings per Share

The ESSA Pharma earnings per share therefore indicates how much revenue ESSA Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ESSA Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ESSA Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ESSA Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ESSA Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ESSA Pharma Revenue, EBIT and net profit per share

DateESSA Pharma Sales per ShareESSA Pharma EBIT per shareESSA Pharma Earnings per Share
2030e13.03 undefined0 undefined4.97 undefined
2029e8.75 undefined0 undefined3.42 undefined
2028e2.48 undefined0 undefined-0.91 undefined
2027e1 undefined0 undefined-1.59 undefined
2026e0.13 undefined0 undefined-0.4 undefined
2025e0 undefined0 undefined-0.51 undefined
2024e0 undefined0 undefined-0.69 undefined
20230 undefined-0.73 undefined-0.6 undefined
20220 undefined-0.84 undefined-0.8 undefined
20210 undefined-0.97 undefined-0.96 undefined
20200 undefined-1.07 undefined-1.05 undefined
20190 undefined-1.44 undefined-1.51 undefined
20180 undefined-2.41 undefined-2.54 undefined
20170 undefined-11.08 undefined-3.1 undefined
20160 undefined-13.85 undefined-9.73 undefined
20150 undefined-17.22 undefined-10.17 undefined
20140 undefined-3.77 undefined-2.32 undefined
20130 undefined-1.31 undefined-1.32 undefined
20120 undefined-2.63 undefined-2.64 undefined
20110 undefined-1.53 undefined-1.53 undefined

ESSA Pharma business model

ESSA Pharma Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of prostate cancer and other types of cancer. The company is headquartered in Vancouver, Canada and was founded in 2009. The history of ESSA Pharma Inc begins with the discovery of a new approach to treating prostate cancer by the company's founders. They discovered that a combination of an androgen receptor inhibitor and a NEDDylation signaling inhibitor could offer a new and effective approach to treating prostate cancer. Based on this discovery, they founded ESSA Pharma Inc to further develop this therapy. ESSA Pharma Inc's business model is based on the discovery, development, and commercialization of therapies for the treatment of prostate cancer and other types of cancer. The company has a pipeline of products in various clinical phases aimed at effectively combating prostate cancer and other types of cancer. ESSA Pharma Inc operates in two main divisions: research and development, and marketing and sales. The company's research and development department is dedicated to identifying and developing new compounds tailored to the specific needs of patients with prostate cancer. The company also works closely with researchers and physicians to test the efficacy of its products in treatment protocols and clinical practice. The second division of ESSA Pharma Inc deals with the marketing and sales of its products. Here, the company works closely with pharmaceutical manufacturers and other companies to market and sell its products worldwide. The company also has its own sales department that serves customers worldwide. ESSA Pharma Inc currently offers several products in different stages of clinical trials. These include EPI-506, an androgen receptor inhibitor currently being used in a Phase 1 study for the treatment of prostate cancer, and EPI-7386, a NEDDylation signaling inhibitor currently in a Phase 1 study for the treatment of prostate cancer. In addition, ESSA Pharma Inc has formed partnerships with other companies to further develop its technology platform and pipeline of cancer therapies. For example, the company is collaborating with Bayer Healthcare to advance the development of EPI-7386. Overall, ESSA Pharma Inc is an innovative and emerging biotech company focused on the development of therapies for the treatment of prostate cancer and other types of cancer. The company is pursuing an ambitious strategy and has already achieved promising results in the development of new compounds for the treatment of prostate cancer. ESSA Pharma is one of the most popular companies on Eulerpool.com.

ESSA Pharma SWOT Analysis

Strengths

1. Strong pipeline of innovative pharmaceutical products.

2. Cutting-edge research and development capabilities.

3. High level of expertise in targeted cancer therapeutics.

Weaknesses

1. Relatively small scale of operations compared to larger pharmaceutical companies.

2. Limited financial resources for large-scale clinical trials.

3. Dependence on a small number of key personnel for research and development.

Opportunities

1. Growing demand for targeted cancer therapies in the global market.

2. Potential partnerships and collaborations with larger pharmaceutical companies.

3. Expansion into new geographic markets with unmet medical needs.

Threats

1. Intense competition from well-established pharmaceutical companies.

2. Stringent regulatory requirements and approval processes.

3. Rapidly evolving landscape of cancer treatment technologies.

ESSA Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

ESSA Pharma historical P/E ratio, EBIT multiple, and P/S ratio

ESSA Pharma shares outstanding

The number of shares was ESSA Pharma in 2023 — This indicates how many shares 44.09 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ESSA Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ESSA Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ESSA Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ESSA Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ESSA Pharma stock splits

In ESSA Pharma's history, there have been no stock splits.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for ESSA Pharma.

ESSA Pharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.25 -0.16  (36.23 %)2024 Q3
3/31/2024-0.19 -0.2  (-4.28 %)2024 Q2
12/31/2023-0.18 -0.14  (20.45 %)2024 Q1
9/30/2023-0.21 -0.12  (43.98 %)2023 Q4
6/30/2023-0.2 -0.17  (14.53 %)2023 Q3
3/31/2023-0.21 -0.16  (23.48 %)2023 Q2
12/31/2022-0.24 -0.15  (37.42 %)2023 Q1
9/30/2022-0.28 -0.14  (50.09 %)2022 Q4
6/30/2022-0.28 -0.2  (27.38 %)2022 Q3
3/31/2022-0.26 -0.25  (2.95 %)2022 Q2
1
2
3

ESSA Pharma shareholders

%
Name
Stocks
Change
Date
19.70856 % BVF Partners L.P.8,748,62906/30/2024
17.77333 % Bellevue Asset Management AG7,889,58306/30/2024
9.48533 % Soleus Capital Management, L.P.4,210,537620,9796/30/2024
9.40831 % Morgan Stanley & Co. LLC4,176,348-7006/30/2024
6.68043 % PFM Health Sciences, LP2,965,442-14,9786/30/2024
5.17833 % RTW Investments L.P.2,298,66206/30/2024
3.32094 % Adage Capital Management, L.P.1,474,165-106,2106/30/2024
2.26673 % Janus Henderson Investors1,006,202-169,0406/30/2024
1.81585 % Rhenman & Partners Asset Management AB806,054-105,7666/30/2024
1.76707 % Berger (Franklin Milan)784,40422,7701/16/2024
1
2
3
4
5
...
8

ESSA Pharma Executives and Management Board

Dr. David Parkinson(72)
ESSA Pharma President, Chief Executive Officer, Director (since 2015)
Compensation 922,003
Mr. Peter Virsik
ESSA Pharma Chief Operating Officer, Executive Vice President
Compensation 675,589
Dr. Alessandra Cesano(63)
ESSA Pharma Chief Medical Officer
Compensation 648,257
Mr. David Wood(62)
ESSA Pharma Chief Financial Officer
Compensation 623,548
Dr. Richard Glickman
ESSA Pharma Non-Executive Independent Chairman of the Board
Compensation 103,109
1
2
3

ESSA Pharma Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer0,18-0,06-0,49-0,65-0,370,20
Bayer Stock
Bayer
SupplierCustomer0,100,33-0,49-0,80-0,20-0,03
Astellas Pharma Stock
Astellas Pharma
SupplierCustomer-0,010,18-0,28-0,59-0,05-0,06
1

Most common questions regarding ESSA Pharma

What values and corporate philosophy does ESSA Pharma represent?

ESSA Pharma Inc represents a values-driven and progressive corporate philosophy. With a focus on innovation, integrity, and collaboration, the company strives to advance novel therapies for the treatment of advanced prostate cancer and other hormonally-driven diseases. ESSA Pharma Inc is committed to delivering breakthrough solutions that improve patient outcomes and quality of life. With a dedicated team of experts and a culture of scientific excellence, ESSA Pharma Inc is driven by a strong commitment to addressing unmet medical needs and revolutionizing the field of oncology.

In which countries and regions is ESSA Pharma primarily present?

ESSA Pharma Inc is primarily present in the United States and Canada.

What significant milestones has the company ESSA Pharma achieved?

ESSA Pharma Inc, a leading pharmaceutical company, has successfully achieved multiple significant milestones. The company made remarkable progress in the development of their product portfolio. Notably, ESSA Pharma Inc received regulatory approvals for several clinical trials, demonstrating their commitment to advancing novel therapies. They also secured strategic partnerships and collaborations with renowned industry players, enabling them to drive further innovation and expand their reach. ESSA Pharma Inc's dedication to researching and developing innovative solutions has positioned them as a key player in the pharmaceutical sector. By focusing on groundbreaking initiatives, they continue to make substantial strides in improving patient outcomes and advancing the field of medicine.

What is the history and background of the company ESSA Pharma?

ESSA Pharma Inc. is a biopharmaceutical company specializing in the development of novel medicines for the treatment of prostate cancer. Founded in 2009, ESSA Pharma has made remarkable strides in advancing targeted therapies to improve patients' outcomes. The company focuses on developing drugs that inhibit the N-terminal domain of the androgen receptor, which plays a vital role in the growth and progression of prostate cancer. With a dedicated team of experienced researchers and a robust pipeline, ESSA Pharma Inc. aims to revolutionize prostate cancer treatment by providing innovative and effective therapies to patients worldwide.

Who are the main competitors of ESSA Pharma in the market?

The main competitors of ESSA Pharma Inc in the market include leading biotechnology companies such as Genentech, Pfizer, Novartis, and Johnson & Johnson. These companies, like ESSA Pharma Inc, are actively involved in the development and commercialization of innovative pharmaceutical products, including therapeutics for oncology and other diseases. In this competitive landscape, ESSA Pharma Inc aims to differentiate itself by focusing on its unique approach to drug discovery and developing cutting-edge therapies that target therapeutically relevant proteins in cancer.

In which industries is ESSA Pharma primarily active?

ESSA Pharma Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of ESSA Pharma?

The business model of ESSA Pharma Inc revolves around the development and commercialization of novel therapies for the treatment of prostate cancer. As a pharmaceutical company, ESSA Pharma Inc focuses on advancing innovative drugs that target the N-terminal domain of the androgen receptor, a key driver of prostate cancer growth. By leveraging its expertise in drug discovery and clinical development, the company aims to provide effective treatment options for patients suffering from advanced prostate cancer. With a strong emphasis on research and development, ESSA Pharma Inc strives to bring transformative therapies to market, ultimately improving the lives of prostate cancer patients.

What is the P/E ratio of ESSA Pharma 2024?

The ESSA Pharma P/E ratio is -2.57.

What is the P/S ratio of ESSA Pharma 2024?

The ESSA Pharma P/S ratio is 0.

What is the Quality Investing of ESSA Pharma?

The Quality Investing for ESSA Pharma is 4/10.

What is the revenue of ESSA Pharma 2024?

The revenue cannot currently be calculated for ESSA Pharma.

How high is the profit of ESSA Pharma 2024?

The expected ESSA Pharma profit is -30.7 M USD.

What is the business model of ESSA Pharma

ESSA Pharma Inc. is a Canadian biopharmaceutical company specializing in the development of innovative therapies for the treatment of cancer. The company focuses on the discovery and development of drugs targeting the androgen receptor (AR) signaling pathway, an important mechanism that contributes to tumor progression in many forms of cancer. The business model of ESSA Pharma Inc. is based on the identification, development, and commercialization of drugs targeting the androgen receptor (AR). The company has focused on the production of new compounds that can inhibit activated androgen receptors. By blocking this protein on the surface of cancer cells, the spread of tumors is expected to be reduced. ESSA Pharma Inc. focuses on the development of pharmaceutical products, with an emphasis on research and development of small molecules that can inhibit the androgen receptor signaling pathway. ESSA is currently in the clinical phase of developing a promising drug called EPI-506. Using an in vitro platform, the company has developed several other molecules that have the potential to be tested in additional clinical trials. The core of ESSA Pharma's business model is the research, development, and commercialization of therapies for the treatment of specific types of cancer, with a focus on prostate cancer. ESSA collaborates closely with experts and researchers in the field of oncology and clinical research to develop the most effective therapies. The company also offers services in the area of clinical trial organization, including support for phase I-II testing, phase III clinical trials, and market strategies. ESSA's services also include the management and operation of clinical trials on behalf of third-party companies. ESSA Pharma's business model is designed for long-term success. By identifying and focusing on a specific target group of cancer patients and collaborating with experienced researchers in the field of oncology and clinical research, the company positions itself as a pioneer and innovator in cancer research. Investments in the research and development of new therapies, as well as the incorporation of expertise in clinical trials and strategies, promote the growth and success of ESSA. Cancer is one of the greatest medical challenges worldwide, and there is a high demand for effective therapies. ESSA Pharma Inc. positions itself as an innovative biopharmaceutical company that is a leader in the treatment of cancer through its research and development of therapies targeting the androgen receptor signaling pathway. With its close collaboration with leading experts in oncology and clinical research, the company is well-positioned to achieve long-term success.

What is the ESSA Pharma dividend?

ESSA Pharma pays a dividend of 0 USD distributed over payouts per year.

How often does ESSA Pharma pay dividends?

The dividend cannot currently be calculated for ESSA Pharma or the company does not pay out a dividend.

What is the ESSA Pharma ISIN?

The ISIN of ESSA Pharma is CA29668H7085.

What is the ESSA Pharma WKN?

The WKN of ESSA Pharma is A2JKQ4.

What is the ESSA Pharma ticker?

The ticker of ESSA Pharma is EPIX.

How much dividend does ESSA Pharma pay?

Over the past 12 months, ESSA Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ESSA Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of ESSA Pharma?

The current dividend yield of ESSA Pharma is .

When does ESSA Pharma pay dividends?

ESSA Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ESSA Pharma?

ESSA Pharma paid dividends every year for the past 0 years.

What is the dividend of ESSA Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ESSA Pharma located?

ESSA Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von ESSA Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ESSA Pharma from 11/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/12/2024.

When did ESSA Pharma pay the last dividend?

The last dividend was paid out on 11/12/2024.

What was the dividend of ESSA Pharma in the year 2023?

In the year 2023, ESSA Pharma distributed 0 USD as dividends.

In which currency does ESSA Pharma pay out the dividend?

The dividends of ESSA Pharma are distributed in USD.

All fundamentals about ESSA Pharma

Our stock analysis for ESSA Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ESSA Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.